Form 4: BridgeBio Pharma Director Acquires RSUs and Options

BridgeBio Pharma Director Frank McCormick reports acquisition of restricted stock units and stock options, with details on beneficial ownership adjustments.

Summary

• Frank McCormick, a Director at BridgeBio Pharma, Inc., has acquired 3,990 restricted stock units (RSUs) on June 22, 2026, with a grant value of $0.
• These RSUs are part of the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan and vest in full on June 22, 2027, contingent on continued service.
• McCormick also acquired a stock option granting the right to buy 5,277 shares of common stock at an exercise price of $68.92, with vesting also set for June 22, 2027, subject to continued service.
• The filing clarifies previous reporting errors, stating that a transfer of 352,290 shares on June 25, 2024, did not occur.
• Beneficial ownership figures have been updated to reflect accurate holdings, including a transfer of 428,976 shares to a trust account on June 3, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, primarily reflecting standard compensation and ownership adjustments for a director rather than significant new strategic information or financial performance indicators.

Positives

• Director McCormick's acquisition of RSUs and stock options indicates continued commitment and alignment with the company's long-term performance.
• The clarification of previous reporting errors demonstrates a commitment to accurate disclosure.
• The transfer of shares to a trust account may indicate long-term wealth planning by the director.

Negatives

• The grant of RSUs has a stated value of $0, which may be a technicality of the grant structure rather than an indication of no value.
• The stock option has a high exercise price of $68.92, suggesting it was granted when the stock price was significantly higher.

Risks

• The vesting of RSUs and stock options is contingent on continued service, meaning failure to remain on the board would result in forfeiture.
• The high exercise price of the stock option may make it unlikely to be exercised if the stock price does not significantly increase.

Future Outlook

The vesting of RSUs and stock options on June 22, 2027, is contingent on the Reporting Person's continued service on the Issuer's board of directors. The stock option has an exercise price of $68.92.

Industry Context

StockSavvy.ai notes that the issuance of RSUs and stock options to directors is a common practice in the biopharmaceutical industry to incentivize long-term performance and align executive interests with shareholders. The specific details of vesting schedules and exercise prices are critical for evaluating the true economic value and potential future dilution.

Stakeholder Impact

• Shareholders: The issuance of RSUs and stock options represents potential future dilution, but also aligns director incentives with long-term company performance.
• Employees: The compensation structure for directors can influence overall employee morale and perception of fairness.
• Management: The filing provides clarity on beneficial ownership, which is important for transparency and regulatory compliance.

Next Steps

• Continued service by Frank McCormick on the BridgeBio Pharma, Inc. board of directors through June 22, 2027, to ensure vesting of RSUs and stock options.
• Potential exercise of stock options if the market price of common stock exceeds $68.92 after vesting.

Key Dates

Keywords

BridgeBio Pharma, BBIO, Form 4, SEC Filing, Insider Trading, Restricted Stock Units, Stock Options, Director Compensation, Beneficial Ownership, Securities Exchange Act